Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 11/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9063028 | 1.00 | CA2 (0.67) | CA2AKR1B1CA1CA9CA12 | |
| SCHEMBL7137894 | 0.83 | CA2 (0.71) | CA2AKR1B1CA1CA9CA12 | |
| SCHEMBL329665 | 0.82 | CA2 (0.69) | CA2AKR1B1CA1CA9CA12 | |
| SCHEMBL16985241 | 0.80 | CA2 (0.67) | CA2AKR1B1CA1CA9CA12 | |
| SCHEMBL1156380 | 0.80 | CA2 (1.00) | CA2AKR1B1CA1CA9CA12 | |
| SCHEMBL31695410 | 0.80 | CA2 (0.67) | CA2AKR1B1CA1CA9CA12 | |
| SCHEMBL1655317 | 0.80 | CA2 (0.67) | CA2AKR1B1CA1CA9CA12 | |
| SCHEMBL29926951 | 0.80 | CA2 (1.00) | CA2AKR1B1CA1CA9CA12 | |
| SCHEMBL4023070 | 0.78 | CA2 (0.65) | CA2AKR1B1CA1CA9CA12 | |
| Hydrochloric Acid SCHEMBL27720604 | 0.78 | CA2 (0.65) | CA2AKR1B1CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112106777-A | Composition containing amino-oligosaccharin and application of composition in potato virus disease | 潍坊华诺生物科技有限公司 | 2020-12-22 | — | — | CN | claimed |
| EP-1265858-B1 | HYDROGEN REDUCTION OF SULFONYL CHLORIDES TO THIOLS | DU PONT (US) | 2004-05-19 | — | — | EP | claimed |
| US-6667421-B2 | Hydrogenating an aryl sulfonyl chloride with hydrogen in a solvent in the presence of a palladium catalyst and a base whose conjugate acid pka is >/=2 | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-12-23 | — | — | US | claimed |
| US-20030055290-A1 | Hydrogen reduction of sulfonyl chlorides to thiols | THE TEXAS A&M UNIVERSITY SYSTEM | 2003-03-20 | — | — | US | claimed |
| EP-1265858-A1 | HYDROGEN REDUCTION OF SULFONYL CHLORIDES TO THIOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001066517-A1 | HYDROGEN REDUCTION OF SULFONYL CHLORIDES TO THIOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-09-13 | — | — | WO | claimed |
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| CN-120136770-A | 3-Aryl-4-sulfonyl-1, 3,4, 5-tetrahydrobenzo [ cd ] -indole compound, preparation method and application thereof | 遵义医科大学 | 2025-06-13 | — | — | CN | disclosed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| WO-2024238574-A1 | CDK INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4436661-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| WO-1990002126-A1 | HYDANTOIN DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355827-A2 | Hydantoin derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
| WO-1989001934-A1 | HYDANTOIN DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1989-03-09 | — | — | WO | disclosed |
| EP-0305947-A1 | Hydantoin derivatives, process for their preparation and pharmaceutical compositions containing the same as well as their use | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1989-03-08 | — | — | EP | disclosed |
| EP-0045196-B1 | HERBICIDAL BENZOTHIOPHENE AND BENZOFURAN SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-11-13 | — | — | EP | disclosed |
| US-4391627-A | Herbicidal benzothiophene and benzofuran sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-07-05 | — | — | US | disclosed |
| EP-0045196-A2 | Herbicidal benzothiophene and benzofuran sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055290-A1 | Hydrogen reduction of sulfonyl chlorides to thiols | TST, IAPP, CBS | CA2 2286/4885AKR1B1 617/4885CA1 1546/4885 |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | CACNA1A, CACNA1E, CACNA1S | CA2 389/4885AKR1B1 1880/4885CA1 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.